Calendario›AMGN›Apremilast · OTELO

Apremilast · OTELO

A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium

Ensayo de AMGEN INC en Psoriasis.

Más ensayos de: Psoriasis.

Fase

no aplica

Estado

Completado

Participantes

124

previstos

Centros

22

Fin del objetivo primario

dic 2018

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en abr 2017.

Qué mide

Proportion of patients with Patient Benefit Index for skin diseases (standard version) (PBI-S) ≥ 1 at 6 months after apremilast initiation. (del registro, en inglés) (hasta 6 meses)

Cómo lo describe el promotor

En el documentoEn inglés, del registroOTELO is a national (Belgium), multicentre, prospective, non-interventional, post-marketing study. The study will include a representative sample of approximately 250 patients with moderate-to-severe plaque psoriasis for whom the treating dermatologist has decided to begin apremilast treatment in accordance with the local label and reimbursement criteria. Patients may be enrolled into the study up to 4 weeks after commencing the study treatment. As this study is non-interventional, drug dosing and treatment duration will be at the sole discretion of the treating dermatologist, in accordance with the local label and daily clinical practice.

Más ensayos de AMGN

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03097003), actualizada en abr 2020.